Skip to main content
Top
Published in: Cancer Causes & Control 12/2019

01-12-2019 | Prostate Cancer | Original Paper

Polymorphisms in oxidative stress pathway genes and prostate cancer risk

Authors: Zhenzhen Zhang, Duo Jiang, Chi Wang, Mark Garzotto, Ryan Kopp, Beth Wilmot, Philippe Thuillier, Andy Dang, Amy Palma, Paige E. Farris, Jackilen Shannon

Published in: Cancer Causes & Control | Issue 12/2019

Login to get access

Abstract

Purpose

Age-related factors including oxidative stress play an important role in prostate carcinogenesis. We hypothesize that germline single-nucleotide polymorphisms (SNPs) in oxidative stress pathway are associated with prostate cancer (PCa) risk. In this study, we aim to examine which of these SNPs is associated with PCa.

Methods

Participants included in this analyses came from the “Genetic Susceptibility, Environment and Prostate Cancer Risk Study” conducted at the Veterans Affairs Portland Health Care System. After applying exclusion criteria, 231 PCa cases and 382 prostate biopsy-negative controls who had genotyping data on twenty-two single-nucleotide polymorphisms (SNPs) in six genes (MAPK14, NRF2, CAT, GPX1, GSTP1, SOD2, and XDH) associated with oxidative stress pathway were included in the analyses. The genotyping of SNPs was conducted by the Illumina BeadXpress VeraCode platform. We investigated these SNPs in relation to overall and aggressive PCa risk using logistic regression models controlling for relevant covariates.

Results

One SNP in the MAPK14 (rs851023) was significantly associated with incident PCa risk. Compared to men carrying two copies of allele A, the presence of one or two copies of the G allele was associated with decreased risk of PCa [OR (95% CI) 0.19 (0.06–0.51)]. There was no statistically significant association between other SNPs in the NRF2, CAT, GPX1, GSTP1, SOD2, and XDH genes and PCa risk.

Conclusions

The MAPK14 gene SNP rs851023 was associated with PCa and aggressive PCa risk after multiple comparison adjustment. Further studies in other populations or functional studies are needed to validate the finding.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRef Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRef
2.
go back to reference Udensi UK, Tchounwou PB (2016) Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp Clin Cancer Res 35:139CrossRef Udensi UK, Tchounwou PB (2016) Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp Clin Cancer Res 35:139CrossRef
3.
go back to reference Oh B, Figtree G, Costa D et al (2016) Oxidative stress in prostate cancer patients: a systematic review of case control studies. Prostate Int 4:71–87CrossRef Oh B, Figtree G, Costa D et al (2016) Oxidative stress in prostate cancer patients: a systematic review of case control studies. Prostate Int 4:71–87CrossRef
4.
go back to reference Kregel KC, Zhang HJ (2007) An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 292:R18–R36CrossRef Kregel KC, Zhang HJ (2007) An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 292:R18–R36CrossRef
5.
go back to reference Roumeguere T, Sfeir J, El Rassy E et al (2017) Oxidative stress and prostatic diseases. Mol Clin Oncol 7:723–728CrossRef Roumeguere T, Sfeir J, El Rassy E et al (2017) Oxidative stress and prostatic diseases. Mol Clin Oncol 7:723–728CrossRef
6.
go back to reference Arsova-Sarafinovska Z, Eken A, Matevska N et al (2009) Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 42:1228–1235CrossRef Arsova-Sarafinovska Z, Eken A, Matevska N et al (2009) Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 42:1228–1235CrossRef
7.
go back to reference Desideri E, Vegliante R, Cardaci S, Nepravishta R, Paci M, Ciriolo MR (2014) MAPK14/p38alpha-dependent modulation of glucose metabolism affects ROS levels and autophagy during starvation. Autophagy 10:1652–1665CrossRef Desideri E, Vegliante R, Cardaci S, Nepravishta R, Paci M, Ciriolo MR (2014) MAPK14/p38alpha-dependent modulation of glucose metabolism affects ROS levels and autophagy during starvation. Autophagy 10:1652–1665CrossRef
8.
go back to reference Abrigo J, Elorza AA, Riedel CA et al (2018) Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev 2018:2063179CrossRef Abrigo J, Elorza AA, Riedel CA et al (2018) Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev 2018:2063179CrossRef
9.
go back to reference Eeles RA, Kote-Jarai Z, Giles GG et al (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316–321CrossRef Eeles RA, Kote-Jarai Z, Giles GG et al (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316–321CrossRef
10.
go back to reference Thomas G, Jacobs KB, Yeager M et al (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310–315CrossRef Thomas G, Jacobs KB, Yeager M et al (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310–315CrossRef
11.
go back to reference Geybels MS, van den Brandt PA, van Schooten FJ, Verhage BA (2015) Oxidative stress-related genetic variants, pro- and antioxidant intake and status, and advanced prostate cancer risk. Cancer Epidemiol Biomark Prev 24:178–186CrossRef Geybels MS, van den Brandt PA, van Schooten FJ, Verhage BA (2015) Oxidative stress-related genetic variants, pro- and antioxidant intake and status, and advanced prostate cancer risk. Cancer Epidemiol Biomark Prev 24:178–186CrossRef
12.
go back to reference Hu J, Feng F, Zhu S et al (2015) Catalase C-262T polymorphism and risk of prostate cancer: evidence from meta-analysis. Gene 558:265–270CrossRef Hu J, Feng F, Zhu S et al (2015) Catalase C-262T polymorphism and risk of prostate cancer: evidence from meta-analysis. Gene 558:265–270CrossRef
13.
go back to reference Ntais C, Polycarpou A, Ioannidis JP (2005) Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 14:176–181 Ntais C, Polycarpou A, Ioannidis JP (2005) Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 14:176–181
14.
go back to reference Martignano F, Gurioli G, Salvi S et al (2016) GSTP1 methylation and protein expression in prostate cancer: diagnostic implications. Dis Mark 2016:4358292 Martignano F, Gurioli G, Salvi S et al (2016) GSTP1 methylation and protein expression in prostate cancer: diagnostic implications. Dis Mark 2016:4358292
15.
go back to reference Men T, Zhang X, Yang J et al (2014) The rs1050450 C > T polymorphism of GPX1 is associated with the risk of bladder but not prostate cancer: evidence from a meta-analysis. Tumour Biol 35:269–275CrossRef Men T, Zhang X, Yang J et al (2014) The rs1050450 C > T polymorphism of GPX1 is associated with the risk of bladder but not prostate cancer: evidence from a meta-analysis. Tumour Biol 35:269–275CrossRef
16.
go back to reference Geybels MS, van den Brandt PA, Schouten LJ et al (2014) Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 106:dju003CrossRef Geybels MS, van den Brandt PA, Schouten LJ et al (2014) Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 106:dju003CrossRef
17.
go back to reference Kang SW (2015) Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis. Int J Clin Exp Med 8:14647–14655PubMedPubMedCentral Kang SW (2015) Superoxide dismutase 2 gene and cancer risk: evidence from an updated meta-analysis. Int J Clin Exp Med 8:14647–14655PubMedPubMedCentral
18.
go back to reference de Jong K, Vonk JM, Imboden M et al (2017) Genes and pathways underlying susceptibility to impaired lung function in the context of environmental tobacco smoke exposure. Respir Res 18:142CrossRef de Jong K, Vonk JM, Imboden M et al (2017) Genes and pathways underlying susceptibility to impaired lung function in the context of environmental tobacco smoke exposure. Respir Res 18:142CrossRef
19.
go back to reference Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO (2011) Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J Signal Transduct 2011:792639CrossRef Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO (2011) Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J Signal Transduct 2011:792639CrossRef
20.
go back to reference Mulholland DJ, Kobayashi N, Ruscetti M et al (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72:1878–1889CrossRef Mulholland DJ, Kobayashi N, Ruscetti M et al (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72:1878–1889CrossRef
21.
go back to reference Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M (2012) MAP kinases and prostate cancer. J Signal Transduct 2012:169170CrossRef Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M (2012) MAP kinases and prostate cancer. J Signal Transduct 2012:169170CrossRef
22.
go back to reference Jiang Y, Chen C, Li Z et al (1996) Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 271:17920–17926CrossRef Jiang Y, Chen C, Li Z et al (1996) Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 271:17920–17926CrossRef
23.
go back to reference Huang X, Chen S, Xu L et al (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65:3470–3478CrossRef Huang X, Chen S, Xu L et al (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65:3470–3478CrossRef
24.
go back to reference Ricote M, Garcia-Tunon I, Bethencourt F et al (2006) The p38 transduction pathway in prostatic neoplasia. J Pathol 208:401–407CrossRef Ricote M, Garcia-Tunon I, Bethencourt F et al (2006) The p38 transduction pathway in prostatic neoplasia. J Pathol 208:401–407CrossRef
25.
go back to reference Zheng Q, Ye J, Wu H, Yu Q, Cao J (2014) Association between mitogen-activated protein kinase kinase kinase 1 polymorphisms and breast cancer susceptibility: a meta-analysis of 20 case-control studies. PLoS ONE 9:e90771CrossRef Zheng Q, Ye J, Wu H, Yu Q, Cao J (2014) Association between mitogen-activated protein kinase kinase kinase 1 polymorphisms and breast cancer susceptibility: a meta-analysis of 20 case-control studies. PLoS ONE 9:e90771CrossRef
Metadata
Title
Polymorphisms in oxidative stress pathway genes and prostate cancer risk
Authors
Zhenzhen Zhang
Duo Jiang
Chi Wang
Mark Garzotto
Ryan Kopp
Beth Wilmot
Philippe Thuillier
Andy Dang
Amy Palma
Paige E. Farris
Jackilen Shannon
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 12/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01242-7

Other articles of this Issue 12/2019

Cancer Causes & Control 12/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine